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EXIMER LASER CORONARY ANGIOPLASTY:INITIAL RESULTS OF A 
MULTICENTER INVESTIGATION IN 958 PATIENTS 
John F. Bresnahan, Frank Litvack, James Margolis, Donald 
Rothbaum, Kenneth Kent, William Untereker, Frank Cummins, 
and the ELCA investigators. Mayo Clinic, Rochester, MN, 
Eximer laser coronary angioplasty (ELCAI is currently 
undergoing clinical investigation to evaluate (1) its 
safety and effectiveness in treating coronary artery 
stenoses(s) and (2) its role in interventional 
cardiology. 1,151 lesions in 958 patients (pts) from 15 
centers underwent laser angioplasty using a 308 nm XeCl 
eximer laser coupled to multifiber over-the-wire 
catheters (C) of 1.3, 1.6, 2.0, and 2.4 mm diameter. The 
pt population consisted of 748 males (78%) and 210 
females (22%) with a mean age of 61 years. 66% of 
patients were in CCSFC III or IV, 30% had undergone prior 
balloon angioplasty CBA), and 26% had previous CABG. Of 
the 1151 lesions treated, 10% were in vein grafts, 10% 
were total occlusions, and 22% were greater than 20 mm in 
length. 41% of the pts were treated with ELCA alone. 
Laser success 020% reduction in S or lumen size 
approximating C-size) was achieved in 85% of lesions; 
procedural success (<SO% residual S) was achieved in 
94%. Stenosis severity was reduced from 86*12% to 48224% 
post ELCA and 25%*20X post 8A. Complications included 
dissection 12.5X, acute occlusion 5.4%. spasm 2X, 
, embolism 0.8% aneurysm 
0.5X, CABG 3.5X, MI 1.4X, and death 0.3%. Preliminary 
follow-up data suggests the restenosis rate is similar to 
8A. Conclusions:-- 1) ELCA is a safe and effective treat- 
mentfor coronary S with early results similar to BA. 
:As;;i; may be particularly indicated for long, diffuse 
3) Restenosis remains a significant problem. 
4) C de;ign and energy delivery continues to evolve and 
may effect future results. 
